Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress

– Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G – – Poster presentation detailing in vitro data showing no significant reduction in serum bactericidal activity with factor D inhibition – NEW

Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference

NEW HAVEN, Conn., May 04, 2018 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8,